Royalty Pharma (RPRX)

• Market cap: $22B
• 1 day: -1.24%
• 5 days: 0.34%
• 1 month: 2.02%
• 3 months: 16.78%
• 6 months: 32.63%
• Year to date: 27.3%
• 1 year: 52.31%
• 5 years: 12.84%
• 10 years: 11.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Employees: 100